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g-Secretase Mutations in Hidradenitis Suppurativa: New
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Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin condition of unclear etiology.
It may segregate as an autosomal dominant trait, and heterozygous mutations in the g-secretase genes NCSTN,
PSENEN, and PSEN1 have recently been reported in a small number of multiplex kindreds and sporadic cases.
These mutations highlight g-secretase (an enzyme that has been extensively investigated in familial Alzheimer’s
disease) to have an integral role in cutaneous biology and, more specifically, in HS. In this article, we review the
recent genetic data, how they inform disease pathogenesis, and the long-term implications in HS and related
diseases.
Journal of Investigative Dermatology (2013) 133, 601–607; doi:10.1038/jid.2012.372; published online 25 October 2012
INTRODUCTION
Hidradenitis suppurativa (HS, acne
inversa, OMIM142690) is a chronic
inflammatory skin condition that pre-
sents with comedones, painful nodules,
abscesses, and sinus tracts in apocrine
gland–bearing areas. Longstanding dis-
ease can result in fibrosis, dermal con-
tractures, significant scarring, formation
of fistulae, and rarely malignant trans-
formation to squamous cell carcinoma
(Losanoff et al., 2011). HS most comm-
only affects the axillae, submammary
folds, abdominal fold, groin, buttocks,
and medial thighs. There is significant
inter-individual variability regarding the
site of the disease, the type of lesions
present, and the associated systemic
response (general malaise, arthralgia,
and rise in inflammatory markers)
during disease flares. The associated
pain, chronic purulent discharge,
persistent malodor, and the involve-
ment of intimate sites in HS can result
in significant patient morbidity (average
DLQI 12.7 in those attending secondary
care; Matusiak et al., 2010). As a result,
the disease can have far reaching social
and economical consequences with
58.7% of patients needing time off
work for an average of 30 days at a
time (Matusiak et al., 2010). In the
absence of any internationally recogni-
zed diagnostic criteria, the diagnosis is
usually based on a clinical history of
chronic, typically painful, inflammatory
lesions in characteristic apocrine gland–
bearing areas (Von Der Werth et al.,
2000). The prevalence is estimated to be
1% in European populations (Jemec
et al., 1996), with an average age of
onset of 21–23 years (Nazary et al.,
2011), and there is a female
predominance (female to male ratios as
high as 5:1; Revuz et al., 2008). The
effective treatment options are limited.
Antibiotics (tetracyclines, clindamycin,
rifampicin), retinoids, dapsone, ciclos-
porin, oral steroids, and anti-tumor
necrosis factor agents offer some
benefit (van Rappard et al., 2012).
HS pathogenesis is poorly under-
stood. It was initially considered a dis-
ease of sweat glands, more specifically
apocrine glands, and was thus named
hidradenitis (inflammation of sweat
glands) suppurativa. More recent histo-
pathological studies, however, suggest
that it is primarily a disorder of follicular
occlusion and that apocrine involve-
ment is a secondary phenomenon
(Boer and Weltevreden, 1996). The
significant associated inflammation has
led some to propose that it may be a
result of aberrant immunity. This
hypothesis is supported by the efficacy
of immunomodulatory agents such as
oral steroids, ciclosporin, and more
recently anti-tumor necrosis factora
therapy in treating the condition (van
Rappard et al., 2011). It is further
supported by the clinical association of
HS with Crohn’s disease (17% of
patients with Crohn’s disease have HS;
van der Zee et al., 2010), where subtle
defects in mucosal immunity have
been shown to have a critical role in
disease pathogenesis (Quaglietta et al.,
2007). The role of bacteria remains
controversial. The lack of a consistent
organism, the failure of patients to
develop infectious complications such
as cellulitis, the normal appearance of
regional lymph nodes, and the efficacy
of oral steroid in HS support more of a
secondary, rather than a primary, role
for bacteria in disease pathogenesis
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(Wortsman et al., 2009). The female
predominance, postpubertal onset,
frequent premenstrual flares (57% of
affected women; Harrison et al., 1988),
and the improvement often observed
during pregnancy and post menopause
(Cornbleet, 1952) indicate a hormonal
influence. No specific hormones, how-
ever, have been implicated. There is a
clear association with smoking (490%
in one study) and obesity (475%;
Alikhan et al., 2009).
A genetic basis for HS was first pro-
posed in the 1980s when Fitzsimmons
and Guilbert (1985) observed that 34%
of first-degree relatives of probands
had the disease. In some kindreds, the
condition appeared to segregate as an
autosomal dominant trait and similar
observations were confirmed in a
follow-up study conducted 15 years
later (Von Der Werth et al., 2000). Up
to 42% of patients with HS report a
family history of the condition (Pink
et al., 2012). Genetic interrogation of
the condition always therefore had the
potential to further our understanding of
disease pathogenesis. Until recently,
only one putative genetic locus had
been reported in HS (80 cM locus on
chromosome 1, 1p21.1-1q25.3; Gao
et al., 2006). More recent genetic ad-
vances, however, have highlighted the
enzyme g-secretase to have a key role in
HS. In this article, we will discuss the
mutations identified in the g-secretase
genes and how they inform the patho-
genic processes underlying the disease.
MUTATIONAL ANALYSIS OF THE
c-SECRETASE GENES REVEALS
MUTATIONS IN NCSTN, PSENEN,
AND PSEN1
Heterozygous mutations were recently
reported in the g-secretase genes PSE-
NEN, PSEN1, and NCSTN in six Chi-
nese multiplex kindreds, all showing full
cosegregation (Wang et al., 2010). One
of these genes, NCSTN, lies within the
previously reported region of linkage
on chromosome 1 (Gao et al., 2006).
Mutations have since been reported in
two British, five Chinese, one Japanese,
and three French multiplex kindreds, as
well as four apparently sporadic cases
(see Table 1, Figure 1) (Wang et al.,
2010; Li et al., 2011; Liu et al., 2011;
Pink et al., 2011; Miskinyte et al., 2012;
Nomura et al., 2012; Zhang et al.,
2012). To date, 17 mutations have
been reported in NCSTN, three in
PSENEN, and one in PSEN1 (Wang
et al., 2010; Li et al., 2011; Liu et al.,
2011; Pink et al., 2011; Miskinyte et al.,
2012; Nomura et al., 2012; Zhang et al.,
2012), of which three are nonsense
mutations, seven result in frameshifts,
seven in altered splicing, and four are
missense mutations (Table 1, Figure 1).
The pattern of mutations and the
Table 1. A table summarizing all of the g-secretase mutations and
corresponding mutant proteins that have been reported in hidradenitis
suppurativa
Gene Mutation Protein
NCSTN c.349 C4T1 p.R117X
c.1300 C4T2 p.R434X
c.1695 T4G3 p.Y565X
c.210_211delAG4 p.T70fsX18
c.487delC2 p.Q163SfsX39
c.1752delG1 p.E584DfsX44
c.1768 A4G2 p.S590AfsX3
c.223G4A5 p.V75I
c.553 G4A6 p.D185N
c. 632 C4G3 p.P211R
c.647A4C5 p.Q216P
c.582þ 1delG7
c.996þ7 G4A6
c.1101þ 1 G4A8
c.1101þ10 A4G6
c.1352þ 1 G4A4
c.1551þ 1 G4A1
PSENEN c.66delG1 p.F23LfsX46
c.66_67insG8 p.F23VfsX98
c.279delC1 p.F94SfsX51
PSEN1 c.725delC1 p.P242LfsX11
1Wang et al., 2010; 2Miskinyte et al., 2012; 3Li et al., 2011; 4Liu et al., 2011; 5Zhang et al., 2012; 6Pink
et al., 2012; 7Nomura et al., 2012; 8Pink et al., 2011.
Presenilin PEN-2 NCSTN APH1
Missense
mutations
Wang et al., 2010
Pink et al., 2011, 2012
Li et al., 2011
Liu et al., 2011
Miskinyte et al., 2012
Nomura et al., 2012
Zhang et al., 2012
Figure 1. The location of all reported mutations within the c-secretase complex in hidradenitis
suppurativa (HS). Mutations are represented as stars. All four missense mutations (p.V75I, p.D185N,
p.P211R, and p.Q216P) in NCSTN are located within the ectodomain. PEN2, presenilin enhancer-2.
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indication that many of the mutant
transcripts are subject to nonsense-
mediated decay suggest that loss of
function of components of the g-secre-
tase complex underlies the disease.
c-SECRETASE IS A FOUR-SUBUNIT
PROTEASE COMPLEX THAT CLEAVES
MULTIPLE TRANSMEMBRANE
PROTEINS INCLUDING AMYLOID
PRECURSOR PROTEIN AND NOTCH
RECEPTORS
g-Secretase is an intramembranous pro-
tease complex capable of cleaving in
excess of 30 type-1 transmembrane
proteins including amyloid precursor
protein, Notch receptors, N-cadherin,
and E-cadherin. The complex is com-
posed of four hydrophobic proteins,
presenilin, presenilin enhancer-2, nicas-
trin, and anterior pharynx defective
encoded by PSEN1/PSEN 2, PSENEN,
NCSTN, and APH1A/ APH1B, respec-
tively (Bergmans and De Strooper,
2010). Presenilin can be encoded by
PSEN1 or PSEN2 and anterior pharynx
defective can be encoded by APH1A or
APH1B, but only one of each can be
present in any one g-secretase complex.
APH1A and APH1B are alternatively
spliced, and thus at least six different
g-secretase variants exist and these may
be tissue- or cell-specific. The complex
contains at least 19 transmembrane
domains but the exact structure and
function of the unit and individual
subunits is not fully understood (Tolia
and De Strooper, 2009).
Presenilin was discovered through
linkage analysis of pedigrees with auto-
somal dominant forms of Alzheimer’s
and was the first part of the g-secretase
complex to be identified (Hutton and
Hardy, 1997). It forms the proteolytic
subunit within the g-secretase complex
(Hutton and Hardy, 1997). Presenilin
enhancer-2 is required for the endo-
proteolysis and activation of presenilin
(Kim and Sisodia, 2005; Prokop et al.,
2005) and the role of APH-1 remains
unclear, but it may act as a scaffold
upon which the complex can be
assembled (Niimura et al., 2005).
Nicastrin is thought to be involved in
complex assembly, maturation, and
stabilization (Chavez-Gutierrez et al.,
2008). It is primarily thought to interact
with the other subunits (presenilin and
anterior pharynx defective) through its
transmembrane domain (Capell et al.,
2003). The role of the ectodomain is
less clear; however, a conformational
change in this domain upon nicastrin
joining the complex is required for
normal g-secretase activity (Shirotani
et al., 2003). Furthermore, mutations
within the DAP domain of the ectodo-
main have been shown to significantly
affect the overall activity of the complex
(Chen et al., 2001). It is noteworthy that
the four missense mutations reported in
HS (p.Val75Ile, p.Asp185Asn, p.Pro211-
Arg, and p.Gln216Pro) (Li et al., 2011;
Pink et al., 2012; Zhang et al., 2012)
are located within the ectodomain
(Figure 1) but outside of the DAP
domain. This supports a key functional
role for this ectodomain within the g-
secretase complex and in HS patho-
genesis.
c-SECRETASE APPEARS INTEGRAL
TO NORMAL SKIN FUNCTION IN
BOTH HUMANS AND ANIMAL
MODELS, POTENTIALLY MEDIATED
THROUGH ITS EFFECTS ON NOTCH
SIGNALING
There are both human and animal data
to functionally support a role for g-
secretase in the skin. A number of
individuals involved in the recent trial
of the g-secretase inhibitor Semagacestat
for Alzheimer’s disease reported cuta-
neous side effects including nonspecific
skin rashes, hair color changes, and an
increased risk of skin cancer (Kelleher
and Shen, 2010; Panza et al., 2010). It
is unclear whether the skin changes
resembled HS; however, the alterations
in hair color would be consistent with a
biological role for g-secretase in the hair
follicle.
A greater body of work has focused
on the function of g-secretase in the skin
of mice where disrupture (PSEN1 /
PSEN2 , PSEN1 , and NCTþ / )
results in follicular keratinization, folli-
cular atrophy, the formation of epider-
mal cysts, absent sebaceous glands, and
epidermal hyperplasia, all histological
features of HS in humans (Xia et al.,
2001; Pan et al., 2004; Li et al., 2007).
These cutaneous manifestations initially
appeared around the nose and mouth,
inguinal and perineal areas, and around
the sebaceous glands of the eyelids and
ears (the post-auricular area, inguinal,
and perineal areas are commonly
affected in HS). Some nodules on
the PSEN1 and NCSTNþ / mice
became dysplastic and developed into
SCC, which may correlate with the rare
development of SCC in HS-affected skin
in humans. g-Secretase would therefore
seem to act as a tumor suppressor in the
skin, a function potentially mediated
by its effects on Notch signaling
(known to be a tumor suppressor) and
EGFR (g-secretase inhibition results in
an upregulation of EGFR, known to be
upregulated in over 90% of head and
neck SCCs; Li et al., 2007).
Mice treated with a g-secretase
enzyme inhibitor (LY-411,575), which
leaves the g-secretase complex intact
and at normal levels, develop lesions
similar to NCTþ / mice (Li et al.,
2007). This therefore suggests that it is
the reduced enzyme activity in the
genetically g-secretase-deficient mice
rather than the effect of any individual
components of the complex that
underlies the skin changes observed.
The fact that mutations have been repor-
ted in three of the four subunits of
g-secretase in familial cases of HS sug-
gests that this is likely to be the case in
humans.
In vivo work in mice suggests that the
skin changes observed in g-secretase-
deficient mice may be partly because of
altered Notch signaling. The hair follicle
and sebaceous glands of mice deficient
in g-secretase are phenotypically iden-
tical to those of mice deficient in Notch
1 and 2 (Pan et al., 2004), and the
additional epidermal changes are pre-
sent in mice deficient in Notch 1, 2, and
3. Notch is a transmembrane receptor
protein involved in cell-to-cell signaling.
Ligand binding to the extracellular
domain of Notch receptors induces
g-secretase-driven cleavage of the intra-
cellular domain, which relocates to the
nucleus and affects gene expression
(Oswald et al., 2001). Within the epi-
dermis, notch signaling is involved
in stem cell clustering, epidermal cell
differentiation, hair follicle differen-
tiation, and epidermal proliferation
(Lowell et al., 2000; Estrach et al.,
2007; Watt et al., 2008). It is involved
in hair follicle and sebaceous gland
maintenance and acts as a tumor
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suppressor by controlling epidermal
proliferation (Proweller et al., 2006;
Lefort et al., 2007).
HETEROZYGOUS MUTATIONS
IN THE PRESENILIN GENES PSEN1
AND PSEN2 ARE ASSOCIATED
WITH FAMILIAL ALZHEIMER’S
DISEASE
The g-secretase complex became a
focus of intense investigation following
the discovery of heterozygous muta-
tions in PSEN1 and PSEN2 in familial
Alzheimer’s disease (FAD; Alzheimer’s
Disease Collaborative Group, 1995).
The majority of mutations reported to
date are heterozygous missense alleles.
Most of these reduce the overall pro-
teolytic activity of the complex (Song
et al., 1999) but increase the length of
b-amyloid peptides produced following
the cleavage of amyloid precursor protein
(APP; b-amyloid deposition forms the
cerebral plaques in FAD; Duff et al.,
1996; Citron et al., 1997). This action of
g-secretase on APP has recently come
under scrutiny and although it appears
that g-secretase cleaves APP, it also
seems to progressively snip (‘‘process’’)
the product. It may therefore be a defect
in processing rather than cleavage that
underlies FAD (Quintero-Monzon et al.,
2011). Interestingly, mutations have
only been identified in a single subunit
of g-secretase (presenilin) in FAD
(including PSEN2 unlike in HS) raising
the possibility that mutant presenilin
may act independently of g-secretase
in causing the disease. One such mech-
anism involves mutations in PSEN1 and
PSEN2 increasing the expression and
activity of b-secretase, another enzyme
that is capable of converting APP to
b-amyloid (Giliberto et al., 2009; Park
et al., 2012).
A key difference between the genetics
of HS and FAD appears to be the nature
of the mutations identified. The vast
majority of mutations identified in HS
are nonsense, frameshift, and splice
site mutations likely to result in haplo-
insufficiency of the relevant genes. In
contrast, the nature of the mutations
identified in FAD (missense mutations)
suggests that the mutant protein needs to
be expressed to affect presenilin/g-secre-
tase activity. Furthermore, mutations
have been identified in three of the four
components of g-secretase in HS imply-
ing that overall enzyme activity is likely
to be important in disease pathogenesis.
As alluded to above, this is not necessa-
rily the prime mechanism by which
presenilin mutations cause FAD. Mutant
presenilin appears to be able to subtly
affect processing (affecting peptide
lengths) and act independently of g-
secretase.
The differing mechanisms that would
appear to underlie these two disparate
diseases go part way to explain why
there is no known clinical association
between the two or reports of FAD in
the mutation-positive multiplex kindreds
with HS. The presence of HS and FAD
in an individual or family should be
interpreted with caution given the pre-
valence of both conditions in the popu-
lation. Even the detection of a mutation
in PSEN1 in such individuals would be
inconclusive given the apparent hetero-
geneity in HS and one would need to
establish firm cosegregation of FAD and
HS within such families.
PATIENTS WITH c-SECRETASE
MUTATIONS HAVE SEVERE,
WIDESPREAD, AND
TREATMENT-RESISTANT
DISEASE THAT IS FREQUENTLY
ASSOCIATED WITH ACNE
CONGLOBATA
It is currently difficult to draw robust
genotype–phenotype correlations; how-
ever, the clinical phenotype of all
reported mutation-positive cases
appears severe and extensive, involving
at least the axillae, groin, and buttocks
in the majority of cases. It is interesting
that individuals harboring 11 of 17
mutations now reported in NCSTN had
a superimposed form of what appeared
to be acne conglobata over their neck,
chest, or back (Wang et al., 2010; Li
et al., 2011; Liu et al., 2011; Nomura
et al., 2012; Zhang et al., 2012). Two
individuals with a heterozygous inser-
tion in PSENEN had a light speckled
hyperpigmentation in the affected areas
(Pink et al., 2011). Many of these
patients had disease that was resistant
to standard therapy and only responded
to Infliximab or surgical intervention
(Pink et al., 2012). The phenotypic
features of this cohort will become
more refined as more cases emerge.
THE IDENTIFICATION OF
c-SECRETASE MUTATIONS
SUGGESTS PRIMARY INVOLVEMENT
OF THE HAIR FOLLICLE RATHER
THAN THE APOCRINE GLAND
IN HS AND SUGGESTS THAT THE
INFLAMMATORY RESPONSE
OBSERVED IS LIKELY SECONDARY
TO PRIMARY FOLLICULAR
OCCLUSION
The identification of g-secretase muta-
tions in HS may inform the longstanding
debate as to whether HS is primarily a
disease of the apocrine gland or the hair
follicle. g-Secretase deficiency in mice
that do not have apocrine glands results
in follicular hyperkeratosis and cyst
formation similar to that seen in human
HS, supporting primary involvement
of the hair follicle in mutation-positive
patients. This is consistent with more
recent histopathological studies in
humans showing that 95% of early
lesions, less than 3 days old, are
associated with a perifolliculitis (more
specifically a spongiform infundibulofol-
liculitis with a mainly T-cell infiltrate),
hyperkeratosis, and occlusion of the fol-
licular unit. Apocrine gland involvement
appeared to be a secondary phenomena
(Yu and Cook, 1990). It remains the case
that the unusual cutaneous distribution
of lesions in HS largely corresponds
with the anatomical location of apo-
crine glands in humans, thus potentially
supporting some involvement in disease
pathogenesis. There are, however, some
notable exceptions, namely the submam-
mary folds, abdominal fold, and medial
thighs.
There is little doubt, both clinically
and histologically, that a significant
inflammatory response accompanies
HS and it has recently been suggested
that a primary immune abnormality may
underlie the condition (van der Zee
et al., 2011). This is supported by the
efficacy of immunomodulatory agents in
treating HS (van Rappard et al., 2011)
and the elevated levels of the pro-
inflammatory cytokines, tumor necrosis
factora and IL-1b, in the blood and skin
of HS patients (the levels of which
correspond with disease severity; Ahmed
et al., 1995; Matusiak et al., 2009; van
der Zee et al., 2011). Although evidence
for an immune response in HS is strong, it
remains unclear whether that is a primary
AE Pink et al.
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event, resulting in the characteristic
follicular occlusion noted on histology,
or secondary to the build up of bacteria
and keratin caused by initial folli-
cular plugging. It is therefore very
interesting to note that g-secretase defi-
ciency (PSEN1 /PSEN2 ) in the skin of
mice resulted in follicular keratiniza-
tion, follicular atrophy, and the forma-
tion of epidermal cysts, but with few
associated signs of inflammation (o20%
cases). A lack of staining to CD3 and
CD45R suggested that inflammation did
not precede the skin changes observed
(Pan et al., 2004). This indicates that
follicular occlusion is likely to occur
before any inflammatory response in indi-
viduals harboring pathogenic g-secretase
mutations.
FUTURE WORK
The functional characterization of the
g-secretase mutations is now critically
important. The effect of these mutations
on g-secretase enzyme activity and
resultant downstream signaling in the
skin needs to be established and the
specific downstream pathways relevant
in HS need to be clarified. Basic ques-
tions, such as the location and composi-
tion of the g-secretase complexes in the
skin, need to be addressed. Another
key question to consider is why the
condition and the disruption of g-secre-
tase affects such specific body sites.
In mice, heterozygous knockout of
PSEN1 ( /þ ) does not result in skin
changes in contrast to full knockout
(PSEN1 / mice) animals. This
implies that a heterozygous mutation
alone cannot result in disease, which
in humans would potentially explain
why the entire skin surface is not
affected. Local factors, for example heat,
sweat, and apocrine secretions in flexu-
ral areas, may be required for disease
development. These factors may be
capable of reducing enzymatic activity
below a critical threshold required for
normal follicular function. The pene-
trance of the g-secretase mutations is
unclear. All adults so far reported to
have mutations had the disease but two
children did not (although they were
under the age of 12, therefore may
go on to develop the disease at a later
age (Wang et al., 2010)). This suggests
that triggering factors are likely to be
universal to everyone (e.g., hormonal
influences) rather than specific to indi-
viduals (e.g., smoking). A further possi-
bility is that reduced g-secretase function
may result in generalized follicular
occlusion, which only becomes clinically
inflamed in the presence of a specific
microbiome (e.g., in warm flexural
areas). Investigation of the many extrin-
sic factors that may contribute toward
disease development will only become
possible as our understanding of the
molecular pathways involved in HS
improves.
It is notable that the majority of
familial and apparently sporadic cases
studied to date had no identifiable
mutations or whole exon or gene
deletions or duplications in NCSTN,
PSENEN, or PSEN1 (Pink et al., 2011;
Miskinyte et al., 2012; Pink et al., 2012).
Only 3 of 48 cases sequentially
recruited from a tertiary referral clinic
had potentially pathogenic variants in
these genes (Pink et al., 2012). Twenty-
five of the 45 mutation-negative cases
were from multiplex kindreds demon-
strating autosomal dominant inheritance,
suggesting that additional and as yet
unknown penetrant alleles predispose
to the development of HS. Alongside
functional work relating to the muta-
tions already identified, ongoing genetic
analysis of the mutation-negative families
is now important in establishing further
disease-causing genes. This would pro-
vide further insight into the mechanisms
by which alterations in g-secretase
result in disease and may highlight
g-secretase-independent pathways.
Potential candidate genes to consider
would be APH1A, APH1B, and PSEN2
as they are directly involved in the
g-secretase complex. Further to these,
given the cutaneous phenotype of
Notch-deficient mice, genes encoding
proteins involved in the Notch signal-
ing pathway are also attractive candi-
dates. The combination of traditional
gene mapping techniques with next-
generation sequencing (whole-exome
or whole-genome sequencing) provides
a powerful platform upon which to
perform this work (Ostergaard et al.,
2011).
These future studies have the poten-
tial to provide insight into the pathogen-
esis of HS and other related conditions
such as acne conglobata, acne vulgaris,
dissecting cellulitis, and pilonidal
abscesses, as well as further our under-
standing of normal hair follicle biology.
Given the widespread distribution and
critical function of g-secretase in the
body, a better understanding of complex
activity in the skin (an easily accessible
site) may provide insight into the patho-
genesis of a broader spectrum of unre-
lated diseases such as FAD.
CONCLUSIONS
Recent work has proven that some
familial and apparently sporadic cases
of HS are single-gene disorders exhibit-
ing autosomal dominant inheritance.
The identification of g-secretase muta-
tions has highlighted a biological path-
way that has never been considered
previously, and the patient cohort with
mutations would appear to represent the
first genetically defined clinical sub-
group of HS. The resulting alteration in
g-secretase function in these patients
may result in HS by affecting down-
stream Notch signaling in the skin.
Further delineation of the mechanisms
and pathways involved will potentially
facilitate the design of novel, more
targeted therapies to treat this debilitat-
ing condition. It should, however, be
noted that these mutations only appear
to underlie a minority of cases and that
it is difficult to relate this enzymatic
pathway with known etiological factors,
such as obesity and smoking. It is there-
fore possible that further, unrelated
biological pathways underlie some
forms of HS. Phenotypic dissection of
this clinically heterogeneous condition
is paramount and would undoubtedly
facilitate further genetic interrogation
of the disease. Ultimately, these subtly
different clinical groups may only
become apparent as our genetic knowl-
edge evolves.
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